证券代码：300888 证券简称：稳健医疗 编号：2023-06 □特定对象调研 □分析师会议 投资者关系活 □媒体采访 □业绩说明会 动类别 □新闻发布会 □路演活动 √现场参观 √其他 （电话会议） Lazard Asset Management-Fisher Xi 参与单位名称 建信理财-肖乐乐 及人员姓名 丹羿投资-龚海刚 中欧基金-王颖、王培 时间 2023 年 6 月 5 日-6 月 16 日 地点 公司总部会议室 上市公司接待 副总经理、董事会秘书：陈惠选 人员姓名 证券部高级 IR：徐佳 一、近期情况介绍： 进入 2023 年，随着经济的整体复苏，各行各业加速回 暖，稳健医疗一季度实现良好开局，业绩增长的步伐也在不 断加快。公司一季度实现营业收入 23.5 亿元，同比增长 投资者关系活 1.3%；归母净利润 3.8 亿元，同比增长 5.6%，整体经营业绩 动主要内容介 表现稳健。需要强调的是，消费板块有明显复苏趋势，一季 绍 度以全棉时代为核心业务的健康生活消费品业务实现营业 收入 9.7 亿元，同比增长 10.5%。医用耗材业务受宏观环境 变化，季度内实现营业收入 13.6 亿元，同比下降 ...

证券代码：300888 证券简称：稳健医疗 公告编号：2023-020 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 稳健医疗用品股份有限公司（以下简称"公司"）《2022 年年度报告》和 《2023 年第一季度报告》已于 2023 年 4 月 25 日对外披露，为使投资者进一步 了解公司的财务状况、经营情况及公司发展规划，公司将于 2023 年 05 月 15 日 （星期一）15:30-16:30 在全景网举行 2022 年报暨 2023 年一季报网上业绩说明 会，本次说明会将采用网络远程方式举行，投资者可登陆全景网"投资者关系互 动平台"http://ir.p5w.net 参与本次业绩说明会。 出席本次业绩说明会的人员有：董事长兼总经理李建全，董事、副总经理兼 首席财务官方修元，副总经理兼董事会秘书陈惠选，独立董事谢家伟。为充分尊 重投资者，提升交流的针对性，现就公司 2022 年报暨 2023 年一季报网上业绩说 明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 05 月 14 日（星期日）15:30 前访问 http ...

证券代码：300888 证券简称：稳健医疗 编号：2023-05 □特定对象调研 □分析师会议 投资者关系活 □媒体采访 □业绩说明会 动类别 □新闻发布会 □路演活动 □现场参观 √其他 （电话会议） 参与单位名称 南方基金、广发基金、华夏基金、万家基金、招商基金等 80 及人员姓名 位机构投资者，名单详见附件（排名不分先后） 时间 2023 年 4 月 26 日 15:30-16:45 地点 线上中金公司、中信证券、海通证券、长江证券、广发证券 联合调研 副总经理兼董事会秘书：陈惠选 稳健医疗轮值 CEO：张燕 上市公司接待 全棉时代副总裁：曾钦华 人员姓名 全棉时代财务管理中心总监：赵霞 稳健医疗财务管理中心副总监：赵燕 证券部高级 IR：徐佳 | --- | |--------------------------------------------------------------| | 一、2022 年度及 2023 年年业绩介绍 | | 面对过往三年复杂的外部环境，公司始终保持战略定力，立足 | | 于医疗和消费两大业务，在"质量优先于利润、品牌优先于速度，社 | | 会价值优先于企业价值"三大 ...

| --- | --- | --- | --- | |-------|--------|--------------|-------------------| | 1 | 王珏 | 安和投资 | 2023 年 4 月 26日 | | 2 | 胡蓉 | 北京诚盛投资 | 2023年4月 26日 | | 3 | 王慧怡 | 北京乐正资管 | 2023年4月 26日 | | 4 | Diana | 彬元资产 | 2023年4月 26日 | | 5 | 邵子馨 | 东方基金 | 2023年4月 26日 | | 6 | 魏宇萌 | 东兴证券 | 2023年4月 26日 | | 7 | 林鲁东 | 广发基金 | 2023年4月 26日 | | 8 | 曹倩雯 | 广发证券 | 2023年4月 26日 | | 9 | 左琴琴 | 广发证券 | 2023年4月 26日 | | 10 | 高峰 | 广发证券 | 2023年4月 26日 | | 11 | 肖辉煌 | 国联证券 | 2023年4月 26日 | | 12 | 陈翠琼 | 国联证券 | 2023年4月 26日 | | 13 | 王佳伟 | 国盛证券 | 2023年4月 ...

Financial Performance - In 2022, the company achieved a total revenue of 11.351 billion yuan, representing a year-on-year growth of 41%[5] - The net profit attributable to shareholders was 1.651 billion yuan, reflecting a year-on-year growth of 33%[5] - The total revenue for 2022 reached ¥11,351,331,545.08, representing a 41.23% increase compared to ¥8,037,420,812.91 in 2021[33] - The net profit attributable to shareholders for 2022 was ¥1,650,582,427.43, up 33.18% from ¥1,239,320,067.26 in the previous year[33] - The net profit after deducting non-recurring gains and losses was ¥1,560,914,973.08, reflecting a 51.69% increase from ¥1,029,005,582.98 in 2021[33] - The net cash flow from operating activities surged by 242.26% to ¥2,983,472,230.27, compared to ¥871,689,901.93 in 2021[33] - The basic earnings per share for 2022 were ¥3.90, up 34.02% from ¥2.91 in 2021[33] - The diluted earnings per share also stood at ¥3.90, reflecting the same growth of 34.02% compared to the previous year[33] - The weighted average return on equity for 2022 was 14.89%, an increase of 3.13% from 11.76% in 2021[33] Revenue Segmentation - The medical consumables segment generated revenue of 7.203 billion yuan, with a remarkable year-on-year increase of 84%[5] - The health consumer products segment reported revenue of 4.055 billion yuan, remaining stable compared to the previous year[5] - Medical consumables accounted for 63.46% of total revenue, with a significant growth of 83.65% from ¥3.92 billion in 2021 to ¥7.20 billion in 2022[136] - The company’s C-end sales exceeded 1.5 billion yuan, showing a robust growth of 51.4% compared to 2021[118] - The company’s B-end (hospital) sales reached 3.62 billion yuan, a significant increase of 190.6% year-on-year[117] Market Expansion and Strategy - The company successfully acquired several firms, including Longtai Medical and Hunan Ping An, expanding its medical product coverage and enhancing its strategic layout for future growth[6] - The company plans to enhance its hospital coverage, particularly in secondary and tertiary hospitals, to leverage its comprehensive product offerings[10] - Future strategies include focusing on "product leadership and operational excellence," with an emphasis on consumer-centric product development and digital management across the supply chain[11] - The company aims to implement a "four high" talent strategy to improve organizational efficiency and achieve strategic goals[11] - The company plans to acquire a 55% stake in Zhejiang Longtai Medical Technology Co., Ltd., indicating a strategy for market expansion and growth[33] Product Innovation and Development - New product innovations include ultra-soft cotton beauty wipes and organic cotton menstrual products, reflecting the company's commitment to consumer preferences and sustainability[9] - The company has expanded its product range from traditional wound care products to comprehensive solutions including wound care, infection protection, and personal health care[76] - The company has developed high-end wound dressings, such as silicone foam dressings and hydrocolloid dressings, targeting chronic wound healing scenarios, with significant potential for import substitution[76] - The company has launched high-end wet wound dressings specifically designed for the fragile skin of elderly patients, addressing clinical pain points associated with traditional gauze dressings[94] - The company has successfully developed and launched biodegradable masks and high-transparency N95 medical protective masks, enhancing comfort and environmental attributes[130] Research and Development - The company increased its R&D expense ratio from 3.7% to 4.3%, focusing on core technology breakthroughs and patent registrations[126] - The company’s R&D investment in 2022 amounted to approximately ¥487.58 million, representing 4.30% of its operating revenue, an increase from 3.71% in 2021[173] - The number of R&D personnel increased by 14.57% from 1,386 in 2021 to 1,588 in 2022, with a notable rise in master's degree holders by 72.88%[172] - The company has established partnerships with various universities and research institutions to enhance its R&D capabilities, including the establishment of the "Wuhan Textile University Innovation Research Institute" for technology transfer[97] Market Trends and Projections - The domestic medical consumables market is projected to reach RMB 3,007 billion by 2022, with an expected growth to RMB 3,427 billion by 2024[52] - The low-value medical consumables market is anticipated to grow to RMB 2,213 billion by 2025, driven by increasing healthcare demands and living standards[56] - The market for surgical infection control products is expected to reach USD 3.688 billion by 2026, with a compound annual growth rate (CAGR) of 4.9%[57] - The customized surgical kits market is projected to grow to USD 21.347 billion globally by 2026, with a CAGR of 10.2%[58] Supply Chain and Operations - The company has established a comprehensive supply chain from procurement to delivery, with over 1 million square meters of production facilities[110] - The company has implemented a digital platform for procurement management, focusing on sustainable supply chain development and risk control[81] - The company has established a complete industrial chain from cotton procurement to R&D, production, and direct export, enhancing its brand value in the medical consumables sector[91] Certifications and Compliance - The company has received FDA approval for multiple wet dressings, with expectations to obtain additional certifications in 2023[130] - The company has received multiple medical device registrations in 2022, including 1 Class III device and 10 Class II devices, enhancing its product portfolio[177] - The company’s certifications include Class A and Class B medical devices, ensuring compliance with international standards for safety and efficacy[181] Financial Position and Investments - The total investment amount for the reporting period was CNY 12,418,231,649.20, representing a 72.44% increase compared to the same period last year[194] - The company completed significant equity investments, including a CNY 727,540,000.00 acquisition of a 55% stake in Longtai Medical and a CNY 450,000,000.00 acquisition of a 100% stake in Guizhou Latex[195] - Cash and cash equivalents increased by 561.71% to CNY 282.21 million in 2022, up from a decrease of CNY -61.12 million in 2021[184]

Revenue and Profit Performance - Revenue for the reporting period was RMB 2,352,114,690.56, a year-on-year increase of 1.28%[4] - Net profit attributable to shareholders of the listed company was RMB 376,938,135.34, a year-on-year increase of 5.56%[4] - Revenue for Q1 2023 reached 2.352 billion yuan, a year-on-year increase of 1.28%[17] - Net profit attributable to shareholders was 377 million yuan, up 5.56% year-on-year[17] - Total revenue for Q1 2023 was 2,352,114,690.56 RMB, a slight increase from 2,322,337,445.27 RMB in the same period last year[23] - Net profit attributable to the parent company was 376,938,135.34 RMB, up from 357,101,020.81 RMB in the previous year[24] - Operating profit increased to 452,706,688.99 RMB from 424,041,383.48 RMB in the same period last year[24] - Comprehensive income for the period totaled RMB 387,215,004.85, with RMB 376,520,909.14 attributable to owners of the parent company[25] - Basic and diluted earnings per share were RMB 0.89, compared to RMB 0.84 in the same period last year[25] Cash Flow and Financial Activities - Net cash flow from operating activities was RMB -223,247,317.38, a year-on-year decrease of 156.20%, mainly due to reduced advance receipts and increased tax payments[5] - Total cash from operating activities increased by 66.42% to 189.31 million yuan[14] - Net cash flow from operating activities was negative RMB 223,247,317.38, compared to positive RMB 397,234,802.12 in the same period last year[27] - Cash received from sales of goods and services was RMB 2,128,547,397.71, a decrease from RMB 2,472,159,804.38 in the previous year[26] - Cash received from investments was RMB 1,414,889,285.00, down from RMB 1,644,215,024.46 in the previous year[27] - Net cash flow from investing activities was negative RMB 178,675,407.47, an improvement from negative RMB 479,044,186.87 in the same period last year[27] - Cash received from financing activities was RMB 683,000,000.00, significantly higher than RMB 100,000,000.00 in the previous year[28] - Net cash flow from financing activities was positive RMB 262,960,743.92, compared to negative RMB 189,666,448.38 in the same period last year[28] - The company's cash and cash equivalents balance at the end of the period was RMB 4,228,193,978.89, down from RMB 4,370,821,958.17 at the beginning of the period[28] Assets and Liabilities - Total assets at the end of the reporting period were RMB 18,029,711,042.27, a decrease of 1.82% compared to the end of the previous year[5] - Total assets decreased to 18,029,711,042.27 RMB from 18,363,337,775.74 RMB at the end of the previous quarter[20][22] - Total liabilities decreased to 5,433,948,305.94 RMB from 6,165,408,250.94 RMB at the end of the previous quarter[21][22] - Inventory decreased to 1,457,644,395.50 RMB from 1,558,923,573.37 RMB at the end of the previous quarter[20] - Total equity increased to 12,595,762,736.33 RMB from 12,197,929,524.80 RMB at the end of the previous quarter[22] - Short-term borrowings increased to 2,423,356,166.66 RMB from 2,295,218,930.85 RMB at the end of the previous quarter[21] - Fixed assets increased to 2,373,863,413.45 RMB from 2,312,982,598.88 RMB at the end of the previous quarter[20] Non-Recurring Items and Other Income - Non-recurring gains and losses amounted to RMB 67,103,259.25, including government subsidies of RMB 19,881,777.62 and gains from financial assets of RMB 57,736,019.94[7] - Other income increased by 49.66% to RMB 19,878,777.62, mainly due to increased government subsidies[11] - Fair value change income increased by 178.75% to RMB 46,133,616.18, mainly due to gains from structured deposits[12] Taxes and Expenses - Taxes paid increased by 200.53% to RMB 290,271,355.72, mainly due to higher corporate income tax and VAT payments[13] - R&D expenses increased to 111,178,989.49 RMB from 94,410,776.54 RMB in the same period last year[23] - Dividend and interest payments increased by 1178.84% to 5.11 million yuan[14] Borrowings and Loans - Long-term loans increased to RMB 200,000,000.00, as the company secured additional long-term bank loans[10] - Borrowings received surged 583% to 683 million yuan[14] Revenue by Product Category - Healthcare consumables revenue decreased by 3.99% to 1.364 billion yuan, with infection protection products revenue dropping 38.21% to 617 million yuan[17] - Regular healthcare consumables revenue surged 76.9% to 747 million yuan[17] - Healthy lifestyle consumer goods revenue grew 10.53% to 969 million yuan, with non-woven consumer goods up 4.3% to 501 million yuan and woven consumer goods up 18.1% to 468 million yuan[17] - Domestic hospital channel revenue fell 38.8% to 429 million yuan due to decreased demand for infection protection products[17] Contract Liabilities and Shareholder Information - Contract liabilities decreased by 58.20% to RMB 236,924,762.49, mainly due to the resumption of normal credit policies for infection protection products[10] - The top shareholder, Wenjian Group Limited, holds 68.10% of the shares, totaling 290.44 million shares[15] Miscellaneous - The first quarter report was unaudited[29]